Stents placed during pancreatic cancer treatment are most commonly used to relieve bile duct blockages, a problem that affects up to 70–90% of patients at some point during their disease.1Europe PMC / Journal of Gastrointestinal Oncology. Biliary stents for pancreas cancer with obstruction: the problem with plastic Pancreatic tumors, especially those in the head of the pancreas, tend to press on or invade the common bile duct, blocking the flow of bile and causing jaundice, intense itching, and a cascade of nutritional and metabolic problems. A stent keeps that duct open so bile can drain. The concept sounds straightforward, but the choices involved, from stent material to timing to placement technique, have real consequences for how treatment unfolds and how you feel day to day.
Why Bile Duct Blockage Matters So Much
When a pancreatic tumor blocks the bile duct, bilirubin builds up in the blood. You turn yellow, your urine darkens, your stool goes pale, and the itching can be relentless. Beyond comfort, the obstruction creates medical problems that interfere with cancer treatment. Liver function deteriorates, clotting factors drop, appetite disappears, and malnutrition sets in. For patients who need chemotherapy, an untreated blockage can delay or derail the entire treatment plan. Studies show that stenting relieves jaundice and pruritus effectively, and also improves appetite and digestion, producing measurable gains in quality of life.2PubMed Central. Symptom relief and quality of life after stenting for malignant bile duct obstruction One study of patients receiving uncovered metal stents found the most complete recovery in jaundice and pruritus, and that most patients scored above the median threshold on quality-of-life measures after stent placement.3PubMed Central. Recurrence of Obstructive Symptoms and Quality of Life after Insertion of Non-Cover Metal Stent Inside the Biliary Duct in Patients with Pancreatic Cancer
Plastic Stents Versus Metal Stents
The two broad categories are plastic stents and self-expandable metal stents (SEMS). Plastic stents are cheaper up front, easy to place, and easy to remove. Their main drawback is that they clog much faster. One study found plastic stents stayed open for a median of about 10 weeks, while metal stents lasted roughly 22 weeks before failing.4PubMed Central. Comparison of therapeutic efficacy and treatment costs of self-expandable metal stents and plastic stents for management of malignant biliary obstruction That gap translates directly into more hospital visits, more repeat procedures, and more days feeling unwell.
The cost picture is less obvious than it first appears. Metal stents cost several times more than plastic ones at the initial procedure, but because plastic stents need replacing sooner, patients who survive more than a couple of months often end up spending as much or more with plastic stents due to repeat procedures and longer hospitalizations.4PubMed Central. Comparison of therapeutic efficacy and treatment costs of self-expandable metal stents and plastic stents for management of malignant biliary obstruction For patients whose expected survival is very short, on the order of a few weeks, a plastic stent may still be the pragmatic choice because it is unlikely to clog in that timeframe. For most others, current evidence favors metal.
Covered, Uncovered, and Partially Covered Metal Stents
Metal stents come in three flavors. Uncovered stents are bare wire mesh. They embed into the duct wall, which keeps them from sliding out of position, but the gaps in the mesh leave room for tumor to grow through, a problem called tumor ingrowth. Fully covered stents have a membrane that blocks ingrowth, but because they do not embed in the wall, they are prone to migrating out of place. A retrospective study confirmed this tradeoff neatly: tumor ingrowth happened only with uncovered stents, and migration happened only with fully covered ones.5PubMed Central. Partially covered metal stents have longer patency than uncovered and fully covered metal stents in the management of distal malignant biliary obstruction: a retrospective study Partially covered stents attempt a compromise: covered in the middle to resist ingrowth, bare at the ends to anchor in place. That same study found partially covered stents had the longest patency of the three designs. Your doctor’s choice among these depends on the exact location and nature of the blockage, whether surgery is planned later, and how long the stent needs to last.
How Stents Are Placed
The standard method is endoscopic retrograde cholangiopancreatography, or ERCP. A flexible scope is passed through the mouth, down through the stomach, and into the duodenum, where the bile duct opens. A wire is threaded into the duct, and the stent is slid into position over the wire. The procedure is done under sedation and typically does not require a surgical incision.
A newer approach is EUS-guided biliary drainage, where an endoscopic ultrasound scope is used to puncture through the stomach or duodenal wall directly into the bile duct. This route is especially useful when tumors have invaded the duodenum and blocked access to the opening where ERCP normally enters. Meta-analyses comparing the two methods as first-line treatments have found similar success rates. Both techniques achieve clinical success in roughly 94–96% of cases, with comparable complication rates, and EUS-guided drainage may carry a lower risk of post-procedure pancreatitis.6PubMed Central. EUS-guided biliary drainage is equivalent to ERCP for primary treatment of malignant distal biliary obstruction: a systematic review and meta-analysis 7Scientific Reports. EUS-guided biliary drainage versus ERCP for first-line palliation of malignant distal biliary obstruction: A systematic review and meta-analysis That said, ERCP remains the first-line choice at most centers because it is a more established technique with wider availability. EUS-guided drainage is typically reserved for when ERCP fails or when the tumor makes the standard approach physically impossible.
Patients who have had prior surgery, such as a Whipple procedure or certain bariatric operations, pose a particular challenge. The rearranged anatomy can make it impossible for a standard side-viewing scope to reach the bile duct opening.8PubMed Central. Endoscopic Biliary Drainage in Surgically Altered Anatomy These patients may need specialized scopes, EUS-guided drainage, or percutaneous approaches where a needle is passed through the skin and liver to reach the bile duct from the outside.
The Preoperative Drainage Debate
If surgery to remove the tumor is planned, the question arises: should you drain the blocked bile duct first and operate later, or go straight to surgery? Intuitively, fixing the jaundice before a major operation seems wise. The evidence, however, is more complicated.
A landmark trial published in the New England Journal of Medicine found that routine preoperative biliary drainage with plastic stents actually increased the rate of serious complications from 39% in patients who went straight to surgery to 74% in those who were drained first.9PubMed. Preoperative Biliary Drainage for Cancer of the Head of the Pancreas The drainage procedure itself introduced infections and other problems that outweighed the benefit of resolving the jaundice before the operation. A more recent meta-analysis confirmed that preoperative drainage is associated with higher rates of surgical site infection, intra-abdominal infection, and sepsis, though it does lower the risk of bile leak after surgery.10PubMed Central. Whether preoperative biliary drainage leads to better patient outcomes of pancreaticoduodenectomy: a meta-analysis and systematic review A network meta-analysis comparing different approaches ranked no preoperative drainage as the best strategy overall for patients heading to surgery.11HPB. Preoperative biliary drainage in resectable pancreatic cancer: a systematic review and network meta-analysis
This does not mean preoperative drainage is never done. When surgery needs to be delayed, whether because of scheduling, a patient’s overall health, or the need for chemotherapy before the operation, a stent becomes necessary to control jaundice in the interim. And when neoadjuvant chemotherapy is involved, the calculus shifts significantly.
Stenting During Neoadjuvant Chemotherapy
Neoadjuvant therapy, chemotherapy given before surgery to shrink the tumor, has become more common in pancreatic cancer. This treatment typically takes several months, during which time a stent must hold the bile duct open. Plastic stents tend to fail during this window, forcing interruptions to chemotherapy for stent exchanges.
Meta-analyses comparing the two stent types specifically in this setting show a large gap. In one analysis, the reintervention rate was about 18% with metal stents versus 80% with plastic stents, and stent-related complications were about 15% versus 44%.12PubMed Central. Stent Selection in Preoperative Biliary Drainage for Patients With Operable Pancreatic Cancer Receiving Neoadjuvant Therapy: A Meta-Analysis and Systematic Review Another meta-analysis found metal stents associated with lower rates of chemotherapy delay, recurrent obstruction, and cholangitis, with no significant differences in surgical outcomes afterward.13PubMed Central. Comparison of metal versus plastic stent for preoperative biliary drainage in patients with pancreatic cancer undergoing neoadjuvant therapy: a meta-analysis and systematic review The implication is clear: if you are going to need a stent in place for months while you receive chemotherapy, metal is the safer bet for keeping treatment on schedule.
When the Tumor Blocks the Gut, Not Just the Bile Duct
Pancreatic tumors can also obstruct the duodenum itself, preventing food from passing through the stomach and small intestine. Patients develop nausea, vomiting, and the inability to eat. Metal stents can be placed in the duodenum to prop the passage open, offering an alternative to surgical bypass. Case reports and series have shown that duodenal stent placement can quickly resolve symptoms like vomiting and restore the ability to eat.14PubMed Central. The Malignant Obstruction Caused by Pancreatic Cancer Within the Uncinate Process in the Third Portion of the Duodenum Uncovered metal stents are generally used in this location because covered stents tend to migrate in the wider, more mobile intestine.
Sometimes both the bile duct and the duodenum are blocked at the same time, a situation called dual obstruction. Managing this requires careful coordination and sometimes creative stent placement strategies, often involving both biliary and enteral stents in the same procedure or a combination of EUS-guided biliary drainage and a duodenal stent.
Endoscopic Stenting Versus Surgical Bypass
For patients whose tumors cannot be removed surgically, the question is whether to manage the bile duct blockage with a stent or with a surgical bypass that reroutes bile around the obstruction. Each approach has tradeoffs that depend heavily on how long the patient is expected to live.
Endoscopic stenting involves a shorter initial hospital stay and lower upfront costs. One cost-effectiveness analysis found the initial stay averaged about seven days for stenting versus 14 for surgery, with charges roughly half as much.15PubMed. Cost-effective analysis of surgical palliation versus endoscopic stenting in the management of unresectable pancreatic cancer But stented patients are more likely to need reinterventions as stents clog or shift over time. A matched study found stented patients had higher rates of reintervention and obstructive complications during follow-up, though overall mortality was similar and total costs of care were still lower for the endoscopic group.16HPB. Early surgical bypass versus endoscopic stent placement in pancreatic cancer
Surgical bypass, when performed in patients who can tolerate it, provides more durable relief. One study found readmission rates were lower in bypass patients than in stented ones, and bypass patients had longer overall survival, though that survival difference may partly reflect the fact that healthier patients are more likely to be offered surgery in the first place.17PubMed Central. Surgical bypass vs. endoscopic stenting for pancreatic ductal adenocarcinoma The general rule of thumb: for patients expected to live many months, surgical bypass may be worth the bigger initial hit. For patients with shorter prognoses or who are not surgical candidates, endoscopic stenting is the less invasive, more practical option.
What Happens When a Stent Clogs or Fails
Stent failure is not a matter of “if” but “when,” especially for patients who survive long enough for the device to wear out. Blockage from sludge, biofilm, tissue overgrowth, or tumor ingrowth is the most common problem. When a metal stent clogs, the options include placing a plastic stent inside it, placing a second metal stent through it, or attempting mechanical cleaning. A study of patients with occluded metal Wallstents found that inserting a second metal stent provided the longest subsequent patency, around 192 days on average, while a plastic stent placed inside lasted about 90 days, and mechanical cleaning alone was rarely effective.18PubMed. Endoscopic management of occluded biliary Wallstents: a cancer center experience
A more insidious problem is the “forgotten” stent. In patients who are too ill for follow-up, who change providers, or who simply fall through the cracks, stents can remain in place far longer than intended. When this happens with plastic stents, severe complications follow. A study of long-term forgotten stents found that nearly all patients developed cholangitis, and about a third had obstructive jaundice. All stent lumens were completely clogged with sludge and stones. Fortunately, endoscopic removal succeeded in over 90% of cases.19PubMed Central. Complications and management of forgotten long-term biliary stents
Stent-Related Events and Their Impact on Chemotherapy
Stent problems do not just cause discomfort. They can derail cancer treatment. A study tracking patients with advanced pancreatobiliary tumors receiving palliative chemotherapy found that 43% experienced a stent-related event during follow-up, with a median time to the first event of about four and a half months. The consequences were serious: roughly a quarter of affected patients had their chemotherapy delayed, about one in six had chemotherapy discontinued entirely, and more than one in five died as a consequence of the stent-related event.20PubMed Central. Impact of biliary stent-related events in patients diagnosed with advanced pancreatobiliary tumours receiving palliative chemotherapy These numbers underline why stent choice and surveillance matter. A clogged stent is not a minor inconvenience; it can change the entire trajectory of cancer care.
Pancreatic Duct Stents and Preventing Post-Procedure Pancreatitis
There is a separate use of stenting that comes up during ERCP and is worth understanding because it confuses many patients. When the scope is used to access the bile duct, the instrument sometimes accidentally enters the pancreatic duct next door. This can trigger pancreatitis, an inflammation of the pancreas that is the most feared complication of ERCP. To prevent it, doctors may place a small temporary stent in the pancreatic duct. A multicenter randomized trial found this reduced the rate of post-ERCP pancreatitis with an odds ratio of 0.43, meaning the risk was cut by more than half. About eight patients needed to be stented to prevent one case of pancreatitis.21PubMed Central. Pancreatic stenting to prevent post-ERCP pancreatitis: a randomized multicenter trial This prophylactic pancreatic stent is typically tiny and falls out on its own within days. It is a different device with a different purpose than the biliary stent placed to relieve the cancer-related blockage, though both may be placed in the same session.22PubMed Central. A Review of Prevention of Post-ERCP Pancreatitis
Radiofrequency Ablation Combined with Stenting
One of the more promising developments in managing bile duct blockages from pancreatic cancer is combining stent placement with radiofrequency ablation (RFA). During ERCP, a special catheter is passed into the bile duct and delivers heat energy to the tumor tissue causing the obstruction. The idea is to burn back the tumor before placing or replacing a stent, giving the stent a longer clear runway.
Evidence suggests this combination works. A review of the literature found that intraductal biliary RFA is safe, effective, and confers a survival advantage over stenting alone.23PubMed Central. Radiofrequency ablation for pancreatobiliary disease: an updated review A propensity-matched study found that patients who received RFA plus a stent had longer stent patency and longer overall survival compared to stent-only patients. After matching, median overall survival was eight months in the RFA-stent group versus four months in the stent-only group.24PubMed Central. Percutaneous endobiliary radiofrequency ablation and stent placement for unresectable malignant biliary obstruction: a propensity score matching retrospective study Whether the survival benefit comes from the ablation directly shrinking tumor or simply from keeping the stent open longer remains an open question.25Frontiers in Oncology. Impact of endobiliary radiofrequency ablation on survival of patients with unresectable cholangiocarcinoma: a narrative review Either way, it is becoming part of the toolkit at specialized centers.
Drug-Eluting Stents
Borrowing a concept from cardiology, researchers have been developing biliary stents coated with chemotherapy drugs. The idea is that the stent slowly releases a drug directly into the surrounding tissue, suppressing the tumor growth that causes the stent to clog. Animal studies using paclitaxel-eluting membranes showed the drug inhibited the growth of pancreatic tumor cells by cutting off their blood supply and triggering cell death.26PubMed Central. Molecular mechanism of local drug delivery with Paclitaxel-eluting membranes in biliary and pancreatic cancer: new application for an old drug Small human pilot studies have been conducted comparing paclitaxel-eluting covered metal stents against standard covered metal stents in patients with malignant biliary obstruction including pancreatic cancer.27Gastrointestinal Endoscopy. Paclitaxel-eluting covered metal stents versus covered metal stents for distal malignant biliary obstruction: a prospective comparative pilot study A review of the field noted that while human trial data remains limited, the early results are promising regarding both safety and potential effectiveness.28PubMed Central. Drug eluting biliary stents to decrease stent failure rates: A review of the literature Drug-eluting biliary stents are not yet standard care, but they represent a direction that could meaningfully reduce the burden of stent failure in the coming years.
The Financial Weight of Stent Care
Pancreatic cancer treatment is expensive by any measure, and the stent-related portion of care adds its own layer of financial strain. Multiple procedures, hospitalizations for stent-related complications, and the cumulative cost of repeated interventions add up, particularly for patients on plastic stents who need more frequent exchanges. Research into financial toxicity among pancreatic cancer patients has found it is driven by out-of-pocket costs, lost employment, and depleted savings, with downstream consequences including treatment nonadherence.29PubMed Central. Risk Factors for Financial Toxicity in Patients With Pancreatic Cancer When a stent complication triggers an unplanned hospital admission or forces a chemotherapy delay, the financial impact compounds the medical one. Asking your care team directly about the expected stent lifespan, the likelihood of needing reinterventions, and the cost difference between stent types is a reasonable and important part of treatment planning.
Patients on Blood Thinners
Many patients with pancreatic cancer are on antiplatelet or anticoagulant medications, either for pre-existing heart conditions or because pancreatic cancer itself raises clotting risk. This creates a practical dilemma: stopping blood thinners increases the risk of a clot, but continuing them risks bleeding during an endoscopic procedure. A single-center study of patients undergoing biliary-pancreatic procedures while on dual antiplatelet therapy found no cases of immediate or delayed significant bleeding, and hemoglobin levels were essentially unchanged before and after the procedure.30PubMed Central. Biliary-Pancreatic Endoscopic and Surgical Procedures in Patients under Dual Antiplatelet Therapy: A Single-Center Study This is reassuring, though decisions about managing blood thinners around stent procedures should always be individualized between your gastroenterologist and cardiologist.